Overview

This trial is active, not recruiting.

Conditions piebaldism, segmental vitiligo
Treatments recell epidermal cell suspension grafting, co2 laser abrasion + uv-therapy
Phase phase 4
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Start date June 2012
End date September 2013
Trial size 10 participants
Trial identifier NCT01640678, METC2012_052

Summary

Autologous epidermal cell suspension grafting is an effective method of surgical treatment in vitiligo, which is suitable for treating larger areas with better cosmetic results as compared to other grafting methods. The ReCell Autologous Cell Harvesting Device (Avita Medical Europe Limited, Cambridge, UK) is an autologous cell harvesting device which, compared to other forms of autologous epidermal cell suspension grafting, is easier in use showing similar results. Furthermore, the ReCell device needs no laboratory facilities. Therefore, it is promising for patients with large vitiligo and piebaldism lesions.

Objectives: Primary: to asses the efficacy and safety of autologous epidermal cell suspension grafting with the ReCell device after CO2 laser abrasion compared to CO2 laser abrasion alone and no treatment, in patients with piebaldism and stable vitiligo. Secondary: to assess the practical aspects and patients satisfaction of autologous epidermal cell suspension grafting with the ReCell device.

Study design: Prospective observer blinded randomized controlled pilot study. Study population: 10 patients ≥ 18 years with stable segmental vitiligo or piebaldism who are under treatment at the Netherlands Institute for Pigment Disorders (NIPD) at the Academic Medical Centre University of Amsterdam.

Methods: Three depigmented regions on the trunk or proximal extremities will be randomly allocated to; CO2 laser abrasion + ReCell autologous cell suspension grafting, or CO2 laser abrasion, or no treatment. After the transplantation, UV-treatment according to the standard treatment protocol of the NIPD will be started on all sites and continued for 3 months. Three and six months after grafting, the percentage of repigmentation of the lesions will be assessed.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
recell epidermal cell suspension grafting
According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
(Active Comparator)
According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
co2 laser abrasion + uv-therapy
According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
(No Intervention)

Primary Outcomes

Measure
degree of repigmentation
time frame: 6 months

Secondary Outcomes

Measure
Visual assessment of side effects per treatment region
time frame: 6 months
General outcome assessed by the patient
time frame: 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - patient with piebaldism - Patients with segmental vitiligo,stable since 12 months without systemic therapy or topical therapy as defined by the absence of new lesions and/or enlargement of existing lesions - with at least three depigmented skin lesions on the proximal extremities or trunk larger than 3x3 cm or one lesion of at least 9x3 cm - Age >18 - willing and able to give written informed consent Exclusion Criteria: - UV therapy or systemic immunosuppressive treatment during the last 12 months - Local treatment of vitiligo during the last 12 months - Vitiligo lesions with follicular or non-follicular repigmentation - Skin type I - Recurrent HSV skin infections - Hypertrophic scars - Keloid - Cardial insufficiency - Patients with a history of hypersensitivity to (UVB or UVA) light and/or allergy to local anesthesia. - Patients who are pregnant or breast-feeding - Patients not competent to understand the procedures involved - Patients with atypical nevi - Patients with a personal history of melanoma or non-melanoma skin cancer

Additional Information

Official title Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study
Trial information was received from ClinicalTrials.gov and was last updated in August 2013.
Information provided to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).